Concepedia

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis,

Journal of Thoracic Oncology · 2018 · 261 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

, , +15

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

, , +14

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

, , +16

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

, , +13